Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

13.50EUR
23 Sep 2016
Change (% chg)

€-0.10 (-0.74%)
Prev Close
€13.60
Open
€13.52
Day's High
€13.58
Day's Low
€13.42
Volume
75,374
Avg. Vol
186,610
52-wk High
€19.09
52-wk Low
€12.13

Latest Key Developments (Source: Significant Developments)

Bayer to explore sale of $1.1 bln dermatology business - Bloomberg
Thursday, 8 Sep 2016 01:06pm EDT 

: Bayer said to explore sale of $1.1 billion dermatology business - Bloomberg, citing source . Bayer is working with J.P. Morgan Chase & Co on the sale, which could fetch more than 1 billion euros ($1.1 billion)- Bloomberg, citing source . Business could attract interest from Nestle Sa's Galderma, Allergan Plc and Almirall Sa of Spain, as well as private equity firms - Bloomberg Further company coverage: [BAYGn.DE] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Almirall reports H1 net profit up at 80.5 million euros
Wednesday, 27 Jul 2016 06:23am EDT 

Almirall SA : H1 net profit 80.5 million euros ($88.53 million) versus 58.8 million euros year ago . Sees 2016 net result, EBITDA percent growth in the upper single digits range year-on-year . Sees 2016 total revenue percent growth in the upper single digits range year-on-year .H1 net sales 388.3 million euros versus 359.4 million euros year ago.  Full Article

Almirall H1 net profit 80.5 mln euros, up 37 pct year on year
Tuesday, 26 Jul 2016 01:56am EDT 

Almirall SA : H1 net profit 80.5 million euros versus 58.8 million euros year ago . H1 EBITDA 123.5 million euros versus 123.4 million euros year ago . H1 revenue 428.1 million euros versus 407.9 million euros year ago . H1 research and development expenses up 35 percent at 44.0 million euros versus 32.6 million euros year ago .Reiterates estimates for 2016.  Full Article

Almirall announces global licensing deal with Patagonia for congenital ichthyosis
Friday, 22 Jul 2016 04:27am EDT 

Almirall SA : Announces global licensing deal with Patagonia Pharmaceuticals for congenital ichthyosis . Almirall and Patagonia will jointly work on development of Patagonia's product PAT-001 . To acquire global marketing rights for the product . Almirall to make an upfront payment of $3.5 million and Patagonia to get development and regulatory milestone payments of up to $24 million .In addition, Patagonia will be eligible to receive sales milestone payments and double-digit royalties on net sales.  Full Article

Almirall's CFO, Daniel Martinez, steps down
Friday, 17 Jun 2016 04:08am EDT 

Almirall SA : Says executive vice-president of finance (CFO), Daniel Martinez, steps down .Says Martinez to leave the post at end-July.  Full Article

Almirall signs US distribution deal with Sinclair Pharma
Monday, 23 May 2016 11:34am EDT 

Almirall SA : Signs through its Dallas based company Thermigen, an exclusive US strategic marketing collaboration agreement for Silhouette Instalift (TM) with Sinclair Pharma Plc .Thermigen has been initially granted with exclusive four-year distribution rights for US market until mid-2020.  Full Article

Almirall and Bicosome to jointly develop topical drug delivery formulations
Friday, 20 May 2016 03:26am EDT 

Almirall SA :Says enters into a collaboration and sublicense agreement with Bicosome to jointly develop topical drug delivery formulations.  Full Article

Almirall Q1 net profit down at 21.7 mln euros
Monday, 9 May 2016 01:59am EDT 

Almirall SA : Q1 EBITDA 54.8 million euros ($62.5 million) versus 73.1 million euros year ago . Q1 net profit 21.7 million euros versus 42.9 million euros year ago . Q1 revenue down 7.5 percent at 201.0 million euros versus year ago . Q1 research and development expenses 19.2 million euros versus 17.5 million euros year ago .Confirms FY 2016 EBITDA, sales, profit growth outlook at constant currency.  Full Article

Almirall SA sells unit and product license in Mexico for 50 mln euros
Tuesday, 15 Mar 2016 11:28am EDT 

Almirall SA:To transfer 100 percent of its Mexico's unit to Grupo Grunenthal for 30 million euros.Reaches perpetual license deal for its products in Mexico for 20 million euros.  Full Article

Almirall SA to propose FY 2015 dividend
Monday, 22 Feb 2016 02:03am EST 

Almirall SA:To propose FY 2015 dividend of 33 million euros, that is 0.19 euro per share.  Full Article

BRIEF-Almirall signs license deal with Sun Pharma for psoriasis treatment

* Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis